NCT03461523 is a clinical trial in ICU Stay & Mortality, sponsored by National Hepatology & Tropical Medicine Research Institute.

Who is sponsoring NCT03461523?

NCT03461523 is sponsored by National Hepatology & Tropical Medicine Research Institute.

What condition does NCT03461523 study?

NCT03461523 studies ICU Stay & Mortality.

Is NCT03461523 still recruiting?

NCT03461523 is currently completed. Last updated 21 February 2021.

Last reviewed 2021-02-21 · How we verify

NCT03461523

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational, Prospective, Single-center Study: Should Body Mass Index (BMI) be Added to the Scoring Criteria of Hepatic Critically Ill Patients in Intensive Care Unit??

Completed Last updated 21 February 2021

What this trial tests

trial in ICU Stay & Mortality in 517 participants. Completed in 19 February 2021.

Timeline

10 February 2018

Primary endpoint
24 June 2020

19 February 2021

Quick facts

Lead sponsor	National Hepatology & Tropical Medicine Research Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	517
Start date	10 February 2018
Primary completion	24 June 2020
Estimated completion	19 February 2021
Sites	1 location across Egypt

Conditions studied

ICU Stay & Mortality — all drugs for ICU Stay & Mortality →

Sponsor

National Hepatology & Tropical Medicine Research Institute

Who can join

Adults 18 to 80, any sex, with ICU Stay & Mortality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the hypothesis of poor clinical outcomes in critically ill patients that are having abnormal BMI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other National Hepatology & Tropical Medicine Research Institute trials

Trials by the same sponsor.

NCT07358741 — Standard Two-Day Advanced Life Support (ALS) Versus One Day Recertification Course · recruiting
NCT07085832 — Assessment of Cardiopumonary Resuscitation (CPR) Competency Post ALS Course · NA · recruiting
NCT06063993 — Evaluation of Perfusion Index Change Post Passive Leg Raising for Fluid Responsiveness in Critically Ill · completed
NCT04750135 — Assessment of Metformin as Adjuvant Therapy in Patients With Ulcerative Colitis · Phase 2 · unknown
NCT04468685 — Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03461523 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Hepatology & Tropical Medicine Research Institute
Last refreshed: 21 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03461523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing